Profile
Sector:
HealthcareIndustry:
Health Information ServicesCountry:
United StatesIPO:
28 March 2012Website:
http://www.tempus.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 13 Sep 2024 23:59:35 GMTDividend
Analysts recommendations
Institutional Ownership
TEM Latest News
In just ten days, shares of the mid-cap healthcare stock Tempus AI NASDAQ: TEM have gone from down 4% to up nearly 60% in 2024. Famed investor Cathie Wood recently increased her allocation to the company through the ARK Invest family of funds.
The recently listed company expanded its shareholding in a biotech. It now owns over 19% of biotech Personalis' common equity.
Tempus AI provides an end-to-end diagnostic platform connecting clinical, molecular, and image data for physicians and pharmaceutical companies. The company's key competitive advantages include broad data collection, a genomics platform, and intelligent diagnostics, positioning Tempus uniquely in the healthcare technology industry. Recent financial results show 25% year-over-year revenue growth, with Softbank's investment indicating disruptive potential in healthcare diagnostics and precision medicine.
William Blair initiated coverage on Tempus AI, Inc TEM, citing the company's ‘differentiated approach and business model.'
Several analysts kicked off coverage of Tempus AI (TEM) with bullish comments, anticipating gains from the biotech company's applications of artificial intelligence (AI) to healthcare.
A number of Wall Street analysts on Tuesday made bullish calls on the shares of a newly public healthcare company that uses artificial intelligence to differentiate itself in the cancer-diagnostics space.
The market for initial public offerings (IPOs), featuring promising new IPOs, has rebounded strongly in 2024, with the number of offerings surpassing last year's total by 40%. The combined valuation of this year's IPOs has more than doubled compared to the previous year, sparking speculation about future public offerings.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotechnology company focused on providing a brighter future for patients through the development of novel pharmaceuticals and technologies. As part of this collaboration, Tempus will develop and investigate AI-based medical device software to detect patients at risk of having undiagnosed pulmonary hyper.
Tempus AI conducted its IPO last week. The healthcare AI company has financial backing from Google.
One large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading - Tempus AI, Telix Pharmaceuticals, Centurion Acquisition, and Perceptive Capital Solutions, respectively. One nanocap is currently scheduled to list in the week ahead, although some other small issuers may join the calendar throughout the week - Nova Minerals. Street research is expected for one company in the week ahead, and lock-up periods will be expiring for one company.
What type of business is Tempus AI?
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a collaboration with united therapeutics to study use of AI to detect patients at risk for pulmonary hypertension. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.
What sector is Tempus AI in?
Tempus AI is in the Healthcare sector
What industry is Tempus AI in?
Tempus AI is in the Health Information Services industry
What country is Tempus AI from?
Tempus AI is headquartered in United States
When did Tempus AI go public?
Tempus AI initial public offering (IPO) was on 28 March 2012
What is Tempus AI website?
https://www.tempus.com
Is Tempus AI in the S&P 500?
No, Tempus AI is not included in the S&P 500 index
Is Tempus AI in the NASDAQ 100?
No, Tempus AI is not included in the NASDAQ 100 index
Is Tempus AI in the Dow Jones?
No, Tempus AI is not included in the Dow Jones index
When was Tempus AI the previous earnings report?
No data
When does Tempus AI earnings report?
The next expected earnings date for Tempus AI is 29 November 2024